Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics
European Journal of Nuclear Medicine and Molecular Imaging · 2024-07 · 51 (8) · 2504-2514
DOI: 10.1007/s00259-024-06681-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 21.03.2024. Verfasst von Grigory Liubchenko und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninstrasse 15, 81377, Munich, Germany. grigory.liubchenko@med.uni-muenche…. Hauptthemen laut MEDLINE: Single Photon Emission Computed Tomography Computed Tomography, Radiometry. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft, Graduate School 2274 “Advanced Medical Physics for image-guided cancer therapy”.
Abstract (Originalsprache)
Purpose
Although 221 Fr and 213 Bi have sufficient gamma emission probabilities, quantitative SPECT after [ 225 Ac]Ac-PSMA-I&T therapy remains challenging due to low therapeutic activities. Furthermore, 221 Fr and 213 Bi may underlie a different pharmacokinetics due to alpha recoil. We conducted a quantitative SPECT study and a urine analysis to investigate the pharmacokinetics of 221 Fr and 213 Bi and the impact on image-based lesion and kidney dosimetry.
Methods
Five patients (7.7 ± 0.2 MBq [ 225 Ac]Ac-PSMA-I&T) underwent an abdominal SPECT/CT (1 h) at 24 and 48 h (Siemens Symbia T2, high-energy collimator, 440 keV/218 keV (width 20%), 78 keV (width 50%)). Quantitative SPECT was reconstructed using MAP-EM with attenuation and transmission-dependent scatter corrections and resolution modelling. Time-activity curves for kidneys (CT-based) and lesions (80% isocontour 24 h) were fitted mono-exponentially. Urine samples collected along with each SPECT/CT were measured in a gamma counter until secular equilibrium was reached.
Results
Mean kidney and lesion effective half-lives were as follows: 213 Bi, 27 ± 6/38 ± 10 h; 221 Fr, 24 ± 6/38 ± 11 h; 78 keV, 23 ± 7/39 ± 13 h. The 213 Bi-to- 221 Fr kidney SUV ratio increased by an average of 9% from 24 to 48 h. Urine analysis revealed an increasing 213 Bi-to- 225 Ac ratio (24 h, 0.98 ± 0.15; 48 h, 1.08 ± 0.09). Mean kidney and lesion absorbed doses were 0.17 ± 0.06 and 0.36 ± 0.1 $${{\text{Sv}}}_{{\text{RBE}}=5}$$ Sv RBE = 5 /MBq using 221 Fr and 213 Bi SPECT images, compared to 0.16 ± 0.05/0.18 ± 0.06 and 0.36 ± 0.1/0.38 ± 0.1 $${{\text{Sv}}}_{{\text{RBE}}=5}$$ Sv RBE = 5 /MBq considering either the 221 Fr or 213 Bi SPECT.
Conclusion
SPECT/CT imaging and urine analysis showed minor differences of up to 10% in the daughter-specific pharmacokinetics. These variances had a minimal impact on the lesion and kidney dosimetry which remained within 8%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninstrasse 15, 81377, Munich, Germany. grigory.liubchenko@med.uni-muenchen.de.
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Marchioninstrasse 15, 81377, Munich, Germany.
- Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
- SyNergy, University of Munich, Munich, Germany.
- DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.
ORCID-Profile: Grigory Liubchenko
Förderung
- Bundesministerium für Bildung und Forschung
- Deutsche Forschungsgemeinschaft
- Graduate School 2274 “Advanced Medical Physics for image-guided cancer therapy”
- Universitätsklinik München
Zitieren
APA
Liubchenko, G., Böning, G., Zacherl, M., Rumiantcev, M., Unterrainer, L. M., Gildehaus, F. J., Brendel, M., Resch, S., Bartenstein, P., Ziegler, S. I., & Delker, A. (2024). Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 51(8), 2504-2514. https://doi.org/10.1007/s00259-024-06681-2
Vancouver
Liubchenko G, Böning G, Zacherl M, Rumiantcev M, Unterrainer LM, Gildehaus FJ, et al. Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging. 2024;51(8):2504-2514. doi:10.1007/s00259-024-06681-2
BibTeX
@article{Liubchenko2024,
author = {Liubchenko, Grigory and Böning, Guido and Zacherl, Mathias and Rumiantcev, Mikhail and Unterrainer, Lena M and Gildehaus, Franz Josef and Brendel, Matthias and Resch, Sandra and Bartenstein, Peter and Ziegler, Sibylle I and Delker, Astrid},
title = {Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
volume = {51},
number = {8},
pages = {2504--2514},
doi = {10.1007/s00259-024-06681-2}
}
EUVIMED